Results 71 to 80 of about 13,620 (98)

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. [PDF]

Cancer Discov
Siegel F, Siegel S, Kotýnková K, Karsli Uzunbas G, Korr D, Tomono H, Andersen S, Denney D, Berger M, Schulze VK, Lewis TA, Kaplan B, Golfier S, Mortier J, Hillig RC, Boemer U, Petersen K, Eis K, Williams S, Rüttinger D, Cherniack AD, Loong HH, Goto K, Grassi P, Meyerson M, Greulich H.   +25 more
europepmc   +1 more source

First- Versus Second- or Subsequent-Line Use of Cyclin-Dependent Kinase 4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic or Recurrent Breast Cancer: A Multicenter, Retrospective Cohort Study. [PDF]

Medicina (Kaunas)
Yao S, Imoto S, Tsuchiya A, Isaka H, Seki H, Asaga S, Yokoi S, Koneri K, Maeda H, Goi T.   +9 more
europepmc   +1 more source

Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status. [PDF]

Chin Med J (Engl)
Yang X, Wang J, An H, He Y, Gan Y, Chen Q, Liu B, Tang W, Fu G, Jiang Z.   +9 more
europepmc   +1 more source

Inhibition of Erb-B2 Receptor Tyrosine Kinase 3 and Associated Regulatory Pathways Potently Impairs Malignant Peripheral Nerve Sheath Tumor Proliferation and Survival

The American Journal of Pathology, 2023
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, currently untreatable Schwann cell-derived neoplasms with hyperactive mitogen-activated protein kinase and mammalian target of rapamycin signaling pathways. To identify potential therapeutic targets, previous studies used genome-scale shRNA screens that implicated the neuregulin-1 ...
Laurel E. Black, Jody F. Longo, Joshua C. Anderson, Steven L. Carroll   +3 more
openaire   +2 more sources

Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition

Gastroenterology, 2017
Drugs that inhibit the erb-b2 receptor tyrosine kinase 2 (ERBB2 or HER2) are the standard treatment of patients with different types of cancer, including HER2-overexpressing gastroesophageal tumors. Unfortunately, cancer cells become resistant to these drugs, so overall these drugs provide little benefit to patients with these tumors.
Ebbing, Eva A., Steins, Anne, Fessler, Evelyn, Stathi, Phylicia, Lesterhuis, Willem Joost, Krishnadath, Kausilia K., Vermeulen, Louis, Medema, Jan Paul, Bijlsma, Maarten F., van Laarhoven, Hanneke W. M.   +9 more
openaire   +2 more sources

Erb-B2 receptor tyrosine kinase 2 knockdown inhibits retinoblastoma progression via Wnt/β-catenin signaling pathway in vitro

JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2021
B, Liu, T, Gao, H Y, Wu, M, Wan
openaire   +2 more sources

Invadopodia, a Kingdom of Non-Receptor Tyrosine Kinases

Cells, 2021
Hava Gil-Henn, Trishna Saha Detroja, Gil-Henn Hava   +2 more
exaly  

Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases

Molecular Cell, 2020
Stefan Knapp, Robert Perttilä, Deep Chatterjee   +2 more
exaly  

Receptor tyrosine kinases regulate signal transduction through a liquid-liquid phase separated state

Molecular Cell, 2022
Polly-Anne Jeffrey, Stephen D Evans, Kin Man Suen   +2 more
exaly  

Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases

Proceedings of the National Academy of Sciences of the United States of America, 2021
Stefan T Arold, Abdullah Aldehaiman, Lydia Wai Ting Cheung   +2 more
exaly